Hepion Pharmaceuticals Appoints James Liddy to Board

What Happened

• Hepion Pharmaceuticals, Inc. (HEPA) filed an 8-K (Item 5.02) reporting that its Board of Directors approved the appointment of James Liddy as a director, effective August 19, 2026.
• The filing states there are no arrangements or understandings between Mr. Liddy and any other person related to his selection, and no transactions between Mr. Liddy and the Company that would require disclosure under Item 404(a) of Regulation S-K.

Key Details

• Appointment effective date: August 19, 2026.
• Filing type: Form 8-K, Item 5.02 (Departure/Election of Directors or Certain Officers).
• Company ticker referenced: HEPA (Hepion Pharmaceuticals, Inc.).
• Company disclosed no related-party transactions or pre-existing agreements regarding the appointment.

Why It Matters

• Board appointments affect corporate governance and oversight; investors should note the new director addition to Hepion’s leadership team.
• The filing signals no related-party concerns tied to this appointment, which is relevant for governance and regulatory transparency.